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Abstract: Recent advances In molecular biology have revealed that a number of
oncogenes (K-ras, erbB-2, and Met) and tumor suppressor genes (p53, p16, APC, and
DCC) contribute to the development of pancreatic cancer. This paper reviewed the
present knowledge of oncogenes and tumor suppressor genes relevant to pancreatic
cancer. Further studies on molecular alterations In pancreatic cancer may lead to a
better understanding of tumor biology, offering a possibility of development of new
diagnostic and therapeutic approaches In the future.
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Introduction
Pancreatic cancer is an important cause of deaths
from cancers in the developed countries including
Japan. It has remained to elucidate its biological
characteristics and also to establish the method for its
early detection. Recent advances in molecular biology
has revealed that a number of oncogenes and tumor
suppressor genes contribute to the development of
pancreatic cancer. Improvement in its prognosis may
be enabled by early molecular diagnosis and gene-
targeting treatment in the future. This paper reviews
the present knowledge of oncogenes and tumor supp-
ressor genes relevant to pancreatic cancer.
K-ras
Ras gene family consists of three kinds of genes:
N-ras, H-ras, and K-ras. Each of the genes encode a
21-kDa protein with GTPase involved in cell growth
and differentiation I). If K-ras was mutated, the protein
seems to lose GTPase activity and thereby to affect the
tumorigenic process by altering the signal transduction
pathway across the membrane2). K-ras point mutation
at codon 12 has been detected in 80-90% of pancreatic
ductal adenocarcinoma3-6).
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In the model of colorectal carcinoma, ras mutations
are considered to be associated with progression of the
neoplastic process, because 10% of adnomas <1.0 cm
in size have as compared with 50% of adenomas>1.0
cm in size have ras mutations?). In pancreatic cancer,
K-ras mutation is not related to clinical course,
metastasis, or prognosis6.8). K-ras point mutation is
known to be often detected in the ductal cell hy-
perplasias adjacent to pancreatic cance~). It is co-
ntroversial whether these lesions are precancerous9). In
animal models,· weekly injection of nitrosamine in-
duced K-ras mutations in 28% of hyperplastic lesions,
48% of papillary hyperplastic lesions, 78% of car-
cinomas-in-situ, and 80% of invasive cancers of the
pancreas. These results suggested that K-ras mutation
is an early event in the multi-step progression to
pancreatic neoplasmlO).
K-ras mutations in pure pancreatic juice (PPJ) have
been identified in attempts to diagnose pancreatic
cancer in early stageI1-13). Some investigatorsI4,15)
reported that K-ras mutation in PPJ preceded the
definitive diagnosis of pancreatic cancer. We also
experienced a case of small pancreatic cancer diagnos-
ed by serial follow-up studies promptly by a positive
K-ras point mutation in ppJI6). However, K-ras muta-
tion from PPJ was reported to be detected in 37-44%
of patients with chronic pancreatitis1?18), and long-
term follow-up of patients with chronic pancreatitis
revealed that no pancreatic cancer developed in mu-
tation-positive patients17). Further studies are needed to
explore the clinical implication of detection of K-ras
mutations in the early diagnosis of pancreatic cancer.
erbB-2
The erbB-2 (Her-2/neu) oncogene encodes a trans-
membrane protein with homology to the epidermal
growth factor receptor. The erbB-2 protein is over-
epressed in 25-58% of pancreatic cancersI9-23). Fre-
quency of erbB-2 protein overexpression depends on
tumor differentiation. Lower expression of erbB-2 was
observed in poorly differentiated adenocarcinoma
than in moderate or well-differentiated adenocar-
cinoma23.24). As the erbB-2 protein is also overexpress-
ed in mucinous hyperplasia of the pancreatic duct, the
erbB-2 is suggested to be a potential mediator of
growth factor-related signal transduction in pancreatic
duct24). Overexpression of erbB-2 was reported to be
inversely related to the survival of patients with
pancreatic cancerO).
The positive rate of serum c-erbB-2 protein was
reported as from 25% to 35%19,22). Although Okada22)
reported that serum c-erbB-2 correlated with me-
tastases and decreased survival rate in patients with
pancreatic cancer, liver function influenced its serum
levelsI9).
Met
The c-Met oncogene encodes MET protein which is
the receptor for hepatocyte growth factor (HGF)25).
Although MET immunoreactiveity was mild in acinar,
ductal, and islet cells of the normal pancreas was , it
was intense in many of the duct-like cancer cell of
human pancreatic adenocarcinoma was intense26).
Since concomitant overexpreesion of HGF was ob-
served in the pancreatic cancer, HGF is suggested to
play a role in proliferation of pancreatic cancer as the
autocrine or paracrine26.2?). MET immunoreactivity
leads to a significantly longer survival than ne-
gative/focal staining28). These data suggest that Met
might have an important pathogenetic role during the
early stages of development of pancreatic cancer8).
p53
The p53 gene, which is localized on the short arm of
chromosome 17, encodes p53 protein. The p53 protein
is believed to playa prominent role in the regulation of
cell cycles. After the identification of the p53, early
observation suggested that p53 might function as an
oncogene, because overexpression of p53 appeared to
cause oncogenic transformation of cells. Several later
studies, however, defined the normal function of the
p53 to be anti-oncogenic because p53-null mice
developed tumors much more29.30). The p53 gene is
inactivated in diverse human cancers by allelic de-
letions, point mutations that result from amino-acid
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substitutions, and rearrangement31.32l. p53 gene mu-
tations are observed in almost half of pancreatic
adenocarcinomas8).
Relationship between p53 mutations and survival in
pancreatic carcinoma is controversia8). Redston et al.33)
found that there was no significant difference in
overall survival between patients with and those
without p53 mutations. In contrast, Nakamori et al.34)
found that the median survival (6.2 months) of the
patients with p53 mutations was significantly shorter
than that (15.0 months) of those without p53 mu-
tations.
Immunohistochemical examination for p53 protein
was known to be useful to detect p53 gene mutation,
because mutated p53 protein had a considerably longer
half-life than wild p53 protein. Further studies have
revealed that p53 protein accumulation is not always
dependent on p53 gene mutation35). Bourdon et al.
reported that stabilization of the p53 protein depended
also on mechanisms other than p53 gene mutation,
such as binding other molecules of cellular origin35l. In
addition, Maacke et al36). reported that p53 protein
overexpression in cytological specimens of PPJ sam-
ples was found in 59% of patients with pancreatitis
and 67% of patients with pancreatic cancer: Ove-
repressed p53 in pancreatitis appears to be wild-type
p53 and may result from DNA damage occurring
during chronic inflammation.
p161CDKN2(MTS1 )
The p16 in the chromosome 9p21 encodes a protein
which inhibits the activity of the cyclin-dependent
kinase 4 (cd4)37). pl6 is called multiple tumor supp-
ressor 1 (MTS1) because inactivation of p16 was
observed in many cancers38). In pancreatic cancer,
Caldas et al.39) reported that pl6 was deleted ho-
mozygously in 15 (41%) and mutated in 14 (38%) of
37 pancreatic carcinomas.
The p16 gene mutations were reported to be more
frequent in culture cell line than in primary
tumors40.4I). The effect of p16 mutations on survival in
pancreatic cancer has not been reported yet.
APC
APe, located on the chromosome 5q21, is the
causative gene of non-polipotic familial adenoma of
the colon. APC is known to participate in the early
stage of multi-step carcinogesis of the colon cancer42l.
This g~ne was found to encode for a cytoplasmic
protein with sequence homology to intermediate fila-
ment proteins such as myosin and keratin43). Although
Horii et al.44) found that APe mutaations was observed
in 40% of pancreatic cancer, another two studies45.46)
showed frequencies below 3% of APe mutations was
below 3%. Further studies are needed on APe gene in
pancreatic cancer.
DCC
Approximately 70% of colon cancers have deletions
in the region of 18q21, which was later found to be the
locus of DCC (deleted in colorectal carcinoma
gene)42). Hohne et al.47) reported that 63.2% of
pancreatic cancers had DCC mutations. They found
that DCC mutations occurred more commonly in
poorly differentiated pancreatic cancer47).
Conclusion
Further studies on molecular alteration in pancreatic
cancer may lead to a better understanding of tumor
biology, offering a possibility of develoOing new
diagnostic and therapeutic approaches in the future.
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要旨:陣痛の予後は惨潅たるものである｡一方で,
最近の分子生物学の分野での研究の進歩により,
遺伝子レベルでの異常が陣痛では数多く存在する
ことも明らかになってきた｡陣痛の予後を改善す
るために,発展が期待される陣痛における遺伝子
診断や遺伝子治療に向けて現在までの陣痛で明ら
かになった癌遺伝子 (k-fas,erbB-2,Met),痛抑制
遺伝子 (p53,p16,APC,DDC)について,概説した｡
